LiberaBio is a preclinical stage biotech that develops new oncology treatments based on the proprietary MPN technology. This nanotechnology actively targets tumor and metastatic cells and delivers small and large molecules to on-surface or intracellular targets. The company is creating new treatments by delivering novel antibodies targeting intracellular oncoproteins.
Sociedade Xeral de Autores e Editores de Galicia, Rúa das Salvadas, O Carme de Abaixo, Vista Alegre, Santiago de Compostela, Santiago, A Coruña, Galicia, 15705, Spain
